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Transplant ineligible patients who achieve a CR with novel chemotherapy agents, have recently been shown to have superior OS. 2 However transplant eligible MM patients who have refractory disease in response to induction therapies (not containing novel agents) have never been shown to have inferior outcomes following HDT-AT, when compared with patients with chemosensitive disease. [3] [4] [5] [6] [7] Whether this paradigm holds true in the era of novel agents requires prospective investigation. The Mayo Clinic group has 8 retrospectively demonstrated that a o50% reduction in 'serum M-protein' after thalidomide or lenalidomide-based induction therapies, predicted inferior OS and progression-free survival (PFS) with HDT-AT. These findings require further validation in order to refine patient selection for HDT-AT.
We assessed the impact of pre-transplant remission status on outcomes of HDT-AT in MM patients receiving novel induction regimens, in a multicenter retrospective analysis. The study cohort consists of 127 consecutive patients who underwent a planned, single autologous transplant within 1-year of starting first-line induction chemotherapy containing at least one novel agent from [2003] [2004] [2005] [2006] [2007] [2008] [2009] . PBPCs were mobilized with CY and filgrastim. All patients received uniform conditioning with melphalan 200 mg/m 2 intravenously on day À2 (melphalan 140 mg/m 2 if serum creatinine was 42 mg/dL). The disease response preand post-transplantation was confirmed by two investigators at each participating institution by using standard criteria. 9 Baseline categorical variables were compared by using Fisher's exact test, whereas continuous variables were compared by Wilcoxon rank-sum test or a two-sample ttest as appropriate. OS and PFS were estimated using the Kaplan-Meier method. OS was defined as the time from transplant to death from any cause, and surviving patients were censored at the last follow-up. PFS from transplantation was calculated using death and disease progression and/ or relapse as events. This study was approved by IRB at all participating institutions. SPSS version 13.0 (IBM, Chicago, IL, USA) was used for statistical analysis.
The baseline characteristics of patients before transplantation are shown in Table 1 . In order to assess the impact of remission status, outcomes of patients achieving at least a PR (chemosensitive-group; n ¼ 110) before HDT-AT were compared with ones not achieving at least a PR (refractorygroup; n ¼ 17). The two groups did not differ significantly in median age, Ig isotype, disease stage, cytogenetics, previous therapy, performance status and CD34 þ cell dose infused (Table 1) . At a median follow-up of 44-months, the 4-year PFS of patients in chemosensitive and refractory groups was 23 and 12% (median PFS 811 vs 446 days; P ¼ 0.32), respectively (Figure 1a) . The 4-year OS in similar order was 66 and 61% (median OS 1653 vs 1509 days; P ¼ 0.72) (Figure 1b) . We also compared outcomes of patients achieving CR or very good partial response (VGPR) (VGPR-group; n ¼ 39) with ones not achieving at least a VGPR (oVGPR-group; n ¼ 88). The 4-year PFS and OS of patients in VGPR group and oVGPR group were 26 vs 20% (P ¼ 0.12) and 87 vs 59% (P ¼ 0.07), respectively (Figures 1c and d) . It is noteworthy that of the 17 patients in the refractory group 8, 2 and 5 patients achieved CR, VGPR and PR, respectively, with HDT-AT. The median PFS and OS of 10 refractory patients who achieved at least a VGPR post HDT-AT was 650 and 1461 days, respectively.
Although recent data have indicated improved transplantation outcomes of MM patients achieving at least VGPR with novel inductions 10 (also seen in our data with trends of improved OS in patients achieving VGPR), we caution that response failure to novel induction regimens should not automatically preclude consideration of HDT-AT in patients with refractory disease. High-dose melphalan remains one of the most active therapies for MM patients, as highlighted by response improvement seen in the majority of refractory patients in our study, which produced a meaningful duration of disease control. In conclusion our limited, multicenter data suggest that until prospective studies prove otherwise, MM patients who are refractory to novel induction therapies should not routinely be considered ineligible for HDT-AT. 
